Eli Lilly (NYSE:LLY) and Dexcom (NSDQ:DXCM) today announced a joint program for U.S. healthcare providers that includes Lilly’s new, rapid-acting Lyumjev mealtime insulin pen and Dexcom G6 continuous glucose monitoring (CGM) systems.
The program is designed to help clinicians use data to inform diabetes management, including promoting the benefits of a new mealtime insulin dose, the companies said in a news release. Lyumjev is a novel formulation of insulin lispro, which Lilly said was developed to speed the absorption of insulin into the bloodstream and reduce A1C levels in adults with diabetes.
Get the full story on our sister site, Drug Delivery Business News.